Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection-Reference-Cited by-同舟云学术

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection

Published:2022-08-16 Issue:8 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

McPherson Jacob¹,Hu Chenlin¹,Begum Khurshida¹,Wang Weiqun¹,Lancaster Chris¹,Gonzales-Luna Anne J.¹,Loveall Caroline¹,Silverman Michael H.²,Alam M. Jahangir¹,Garey Kevin W.¹^ORCID

Affiliation:

1. University of Houston College of Pharmacy, Houston, Texas, USA

2. Acurx Pharmaceuticals, Staten Island, New York, USA

Abstract

Reduction of Clostridioides difficile infection (CDI) recurrence is an essential endpoint for CDI-directed antibiotic development that is often not evaluated until Phase III trials. The purpose of this project was to use a functional and metagenomic approach to predict the potential anti-CDI recurrence effect of ibezapolstat, a DNA polymerase IIIC inhibitor, in clinical development for CDI.

Funder

Acurx Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02244-21

Reference33 articles.

1. Burden of Clostridium difficile Infection in the United States

2. Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile

3. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults